Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 17Genitourinary 7Plasma cell 4Tumor-Agnostic 2Thoracic 2Head & Neck 2Dermatologic 2Sarcoma 1Myeloid 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 2Bone Diseases 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Denosumab × Plasma cell × Clear all
NCT02833610 2026-02-18

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Massachusetts General Hospital

Phase 2 Completed
55 enrolled
Plasma cell

Multiple Myeloma

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

University of Rochester

Phase 2 Completed
20 enrolled 8 charts
Plasma cell

Smoldering Multiple Myeloma

NCT03792763 2025-02-11

DEFENCE

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 2 Completed
8 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06314698 2024-03-18

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

RenJi Hospital

Phase 3 Not yet recruiting
478 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡